What the FDA’s CAR-T REMS Removal Means for the Future of Cell Therapy Manufacturing
What the FDA’s CAR-T REMS Removal Means for the Future of Cell Therapy Manufacturing A New Era for Autologous CAR-T Therapies In a pivotal move for the field of cell and gene therapy, the FDA recently eliminated the Risk Evaluation and Mitigation Strategies (REMS) requirements for autologous CAR-T therapies. This recent FDA CAR-T REMS removal … Continue reading What the FDA’s CAR-T REMS Removal Means for the Future of Cell Therapy Manufacturing
